What's Behind the Rally in Pharma Stocks?

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

What's Behind the Rally in Pharma Stocks?

May 11, 2021

Pharma stocks are in focus today as a US drug-maker issued voluntary licenses to produce its Baricitinib drug in India to help combat the second wave of COVID-19 in India.

US drug-maker Eli Lilly has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries to manufacture and distribute Baricitinib in India.

Lilly said it was also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.

In addition to voluntary licenses, Eli Lilly said it had made donation of 400,000 Baricitinib tablets immediately available through the humanitarian aid organisation, Direct Relief to the Indian government

Recent Developments that are Aiding the Pharma Rally

Market participants were tracking Sun Pharmaceutical Industries, Cipla, and Lupin on the back of above news.

Sun Pharmaceutical Industries share price was up over 2% in the morning session today and was also the top sectoral gainer, rallying 5% in the last two days.

Sun Pharma hit a four-year high of Rs 721.90, up over 2% in intra-day trade today. The stock was trading at its highest level since April 2017.

Apart from above, healthcare stocks including hospital and laboratory operators have also been witnessing buying interest lately after the Reserve Bank of India (RBI) announced additional liquidity to key sectors participating in tackling the coronavirus crisis.

Reserve Bank of India Governor Shaktikanta Das last week said India's central bank will give Rs 500 bn in liquidity to key sectors.

Banks can provide fresh lending support to pathology labs, oxygen suppliers, vaccine makers, and hospitals under the priority-sector classification of lending.

The BSE Healthcare Index gained as much as 2.7% on the back of above news, the most in almost a month to trade just shy of its 52-week high.

Vaccine makers Cadila Healthcare and Dr Reddy's Laboratories have also witnessed buying recently after Pfizer Inc laid out a plan to turn its Covid-19 vaccine into a long-term business.

The US drug maker also boosted this year's guidance for revenue from the jabs to about US$ 26 bn from a previous forecast of around US$ 15 bn.

Pfizer said it expects to deliver 1.6 bn doses this year under contracts signed as of mid-April.

Strong Performance by Pharma Companies

The recent gains in pharma stocks are also led by a strong performance by pharma companies in the domestic market in April, tie-ups by Indian generic players to market Covid-related drugs and expectations of a double digit growth in the March quarter.

Indian Pharma Market (IPM) sales for April 2021 showed an unprecedented 51.5% growth year-on-year (YoY).

Adjusting for the low base effect and excess Covid sales, April YoY growth is at 17.7%.

Reports suggest that there is likely a component of stocking up as many states entered lockdowns during April.

Equitymaster's View on the Pharma Sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks.

    As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

Nifty Pharma Index Hits All-Time High

The Nifty Pharma index hit an all-time high of 14,228, after rising 3.5% in intra-day trade on Monday, led by a strong rally in stocks like Torrent Pharma, Alkem Laboratories, Cadila Healthcare, Aurobindo Pharma, Dr Reddy's Laboratories, Sun Pharma and Divi's Labs.

The index surpassed its previous high of 14,020.70, touched in intra-day trade on 7 April 2015.

Since last month, the Nifty Pharma index has outperformed the NSE Nifty index by surging 15%, against 1.7% gain in the benchmark.

How the BSE Healthcare Index Has Performed Over Last Year

Over the last year, the BSE healthcare index has gained 61% as compared to 56% gains in the BSE Sensex.

For more detailed updates, you can have a look at Indian pharma sector report and Indian pharma sector results on our website.

You can also compare pharma companies with their peers.

Sun Pharma vs Cipla

Sun Pharma vs Lupin

Cipla vs Dr Reddy's Lab

Aurobindo Pharma vs Biocon

Cadila Healthcare vs Divi's Lab

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Monish Vora

Monish Vora is a keen student of the markets and shares his observations through his clear and concise commentary.

Equitymaster requests your view! Post a comment on "What's Behind the Rally in Pharma Stocks?". Click here!

  

More Views on News

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

IPO Alert! 3 Companies Including PharmEasy Get the Green Light (Views On News)

Feb 22, 2022

The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.

More Views on News

Most Popular

All You Need To Know About Primary And Secondary Markets

A look at the various types of primary and secondary markets and the key differences between them.

2022's Best Performing Penny Stocks So Far... (Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022 (Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


May 23, 2022 (Close)

MARKET STATS